PFE Reaches Post-2024 High as Healthcare ETF Draws Bids

Pfizer (PFE) climbs to its highest close since October 2024 while Solventum posts a 52-week record as capital rotates into defensive dividend-paying healthcare.

Lead

Pfizer Inc. (PFE) advanced to $29.09 on Tuesday -- the top of its 52-week range and its highest close since October 2024 -- as institutional investors accelerated a rotation away from rate-sensitive technology equities and into dividend-bearing healthcare names. Solventum Corporation (SOLV), spun out of 3M Company (MMM) in April 2024, simultaneously reached a fresh 52-week high above $93, underscoring the breadth of capital flowing into healthcare as stagflation risk pricing approaches consensus. The Health Care Select Sector SPDR Fund (XLV) -- the dominant healthcare ETF by assets -- has absorbed consistent institutional inflows through the third quarter, with the sector's combination of inelastic demand, below-market valuations, and durable dividend profiles proving difficult for income-mandated managers to ignore.

Why Are Healthcare Stocks Rising Now?

Medical demand does not compress with GDP, which is precisely why capital moves to healthcare when stagflation signals accumulate. U.S. April 2026 consumer prices rose 3.8% year-on-year while the producer price index surged 6%, the steepest reading since December 2022. Markets now assign roughly a 40% probability to a stagflationary regime taking hold by year-end -- a figure that has steadily lifted appetite for healthcare names carrying earnings visibility that most other sectors cannot match at current valuation levels. The sector's forward price-to-earnings ratio of 18.7 compares to the broader S&P 500's 22.2, a discount that institutional portfolio managers cite as one of the more straightforward valuation arguments available in a compressed-multiple environment.

The rotation picked up breadth in March 2026, when investors began aggressively liquidating positions in technology-heavy funds and redirecting capital into consumer staples and healthcare. That migration has persisted, and Tuesday's session indicates fresh buyers are still arriving.

PFE: Dividend Yield and Earnings Convergence Drive the Move

Pfizer's advance to $29.09 rests on two converging factors: a 7% forward dividend yield that commands attention in an income-constrained environment, and a second-quarter earnings report that cleared consensus on both headline measures. Pfizer posted Q2 adjusted EPS of $0.77 against a $0.68 estimate, with revenue of $15.03 billion clearing the $14.41 billion forecast. Strength came from Eliquis and a broader portfolio of non-COVID products, which outperformed internal projections by approximately $1.5 billion.

Management raised the midpoint of full-year 2026 revenue guidance by $500 million to $61.5 billion -- a range of $60.5 billion to $62.5 billion -- while reaffirming adjusted diluted EPS guidance of $2.80 to $3.00. The company also declared its 351st consecutive quarterly dividend at $0.43 per share, a streak that defines the stock's appeal to income-focused institutional mandates and distinguishes it from peers whose payouts carry less certainty during earnings transitions.

Pfizer is additionally advancing a late-stage pipeline expected to produce multiple pivotal readouts over the next twelve months, with an obesity program gaining clinical momentum and an oncology portfolio positioned as a recurring earnings growth lever. The company has committed to $9.7 billion in net cost savings through 2029, a structural efficiency program that addresses concerns around an elevated payout ratio and signals that dividend sustainability is a deliberate capital allocation priority.

What Is Driving Solventum to a 52-Week High?

Solventum's record close reflects an independent but complementary catalyst: a post-spinoff re-rating supported by accelerating fundamentals. The company posted Q2 2026 organic sales growth of 9.5%, with adjusted EPS of $2.55 rising 50.9% year-on-year. All three segments contributed: MedSurg gained from negative pressure wound therapy and antimicrobial IV-site management products, Dental Solutions benefited from restorative and aesthetic offerings, and Health Information Systems maintained momentum in revenue cycle management.

Full-year 2026 guidance was raised across every metric. Organic sales growth is now projected at 2.5% to 3%, up from the prior floor, while adjusted EPS guidance increased to $7.10-$7.20, a meaningful step up from the prior $6.40-$6.60 ceiling. Solventum is simultaneously nearing full operational independence from 3M, with nearly 70% of roughly 200 transition service agreements exited and approximately 950 of 1,200 systems migrated -- management expects 90% completion by year-end. The company has also announced plans to spin off its Health Information Systems business, a move that would convert SOLV into a tighter, pure-play medical device operator.

Investors who discounted the stock at the time of its 3M separation for the complexity of a nascent carve-out structure are repricing those risks away as independence becomes operational reality.

Sector Rotation: Growth Exits, Defensive Dividend Payers Fill the Void

The dominant capital flow narrative of the third quarter is the withdrawal from technology and the re-entry into defensives. The QQQ has faced multiple compression as rate-cut expectations remain constrained, freeing capital that has found a home in the pharma ETF and broader healthcare fund categories. XLV, the most liquid healthcare ETF vehicle, has been the primary beneficiary. The SPDR S&P Biotech ETF (XBI), which tracks development-stage companies without the same earnings visibility, has not participated to the same degree -- the rotation has concentrated deliberately in profitable, dividend-paying healthcare businesses rather than the sector's speculative subsectors.

This concentration in cash-generating large-caps reflects a calculated preference for duration reduction. Companies like Pfizer with predictable quarterly payouts function as shorter-duration equity instruments than high-multiple growth names, making them direct beneficiaries when markets price higher-for-longer inflation scenarios. Healthcare's forward P/E discount to the index amplifies that attractiveness for managers whose mandates weight value alongside income.

Outlook

Pfizer's break to its highest close since October 2024 and Solventum's 52-week high -- registered on the same session -- confirm that the healthcare sector's stagflation-buffer status is now supported by earnings evidence as much as macro thesis. Both companies have raised guidance, demonstrated operational execution, and offer either dividend income or restructuring upside that keeps the investment case intact across rate scenarios. Whether the defensive rotation extends into the fourth quarter depends heavily on upcoming inflation data and the Federal Reserve's response posture. For now, the market is expressing a clear directional preference: income, earnings visibility, and valuation discipline over growth optionality.